Skip to main content
. 2017 Jul 26;7:6554. doi: 10.1038/s41598-017-06914-5

Figure 3.

Figure 3

GSK-J4 suppresses a specific subset of LPS-inducible genes in PM and BV-2 microglial cells. (A,B) A Venn diagram displaying the number of LPS-inducible genes that were suppressed or up-regulated with GSK-J4 treatment at 4-h after LPS stimulation in the PM and BV-2 microglial cells respectively. (C,D) Heat map representation depicting the positive regulators of inflammatory genes (cytokines, chemokines, IRGs, and undetected genes related to inflammation) that were selectively down-regulated by GSK-J4 at 4-h after LPS stimulation in PM (P ≤ 0.01, and log2-fold change ≥1.5) and BV-2 microglial cells (P ≤ 0.01, and fold change ≥1.5) experiments, respectively. Heat maps were generated with the Multi Experiment Viewer (version 4.8) software. (E,F) UCSC Browser images representing the normalized RNA-seq read density in GSK-J4-down-regulated inflammatory genes at 4-h in the LPS-induced PM and BV-2 microglial cells compared with controls, respectively. (G,H) Transcript abundance (in read count) was evaluated using RNA-seq in GSK-J4-down-regulated inflammatory genes at 4-h in the LPS-induced PM and BV-2 microglial cells, respectively. (I) The area of overlap indicates the number of unique or shared GSK-J4 down-regulated genes after 4-h of LPS stimulation in PM and BV-2 microglial cells.